Understanding how 3D structures in DNA affect leukemia and lymphoma
Official title: Mapping and targeting 3D regulatory elements in leukemia and lymphoma
Funded at New York University School of Medicine · NIH-11070765 · Data updated 2026-11-12
This study is looking at how the way our DNA is organized can affect the development and treatment of leukemia and lymphoma, with the hope of finding new ways to tailor treatments based on each patient's unique genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 13, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $690,772 |
| NIH project number | 1R01CA298153-01 |
| Project ID | NIH-11070765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute T-cell leukemia or lymphoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with acute T-cell leukemia or lymphoma may not benefit from this research.
What this research studies
This research investigates the role of 3D chromatin architecture in the development and treatment response of leukemia and lymphoma. By examining how genetic and epigenetic changes influence the structure of DNA, the study aims to identify critical regulatory elements that could be targeted for therapy. The approach includes advanced techniques to analyze chromatin interactions and their impact on gene expression, particularly in T-cell acute lymphoblastic leukemia. Patients may benefit from insights that could lead to more effective treatment strategies based on their unique genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatments for patients with leukemia and lymphoma.
How similar studies have gone: Other research has shown promise in targeting epigenetic modifications in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Aifantis, Iannis — New York University School of Medicine
- Study coordinator: Aifantis, Iannis
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow grafting and cellular therapies for leukemia and lymphoma
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
-
Inhibiting T-cell Signaling to Treat Adult ATLL
A study to test whether blocking T-cell receptor signaling can help treat adult T-cell leukemia/lymphoma caused by HTLV-1, potentially improving outcomes for patients.
-
Understanding EP300 deficiency in ATLL in adults
This grant explores how loss of EP300 affects an aggressive adult T-cell cancer (ATLL) to identify new ways to help patients.
-
3D gene switches in leukemia and lymphoma
Researchers will map and try to block 3D gene-control hubs that help T-cell leukemia and lymphoma cells grow, aiming to find new ways to help people with these cancers.
-
Improving bone marrow transplants and cell therapies for leukemia and lymphoma
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
-
Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.